$NIXX
Nixxy, Inc. Stock $nixx

$nixx Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000165495422004330 Filed on March 31, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$8.381M	$22.18M	$2.344M
YoY Change	257.51%	160.9%	22.32%
Cost Of Revenue	$5.755M	$14.91M	$1.591M
YoY Change	261.61%	142.89%	6.49%
Gross Profit	$2.626M	$7.275M	$752.8K
YoY Change	248.84%	207.66%	78.39%
Gross Profit Margin	31.33%	32.79%	32.11%
Selling, General & Admin	$7.034M	$17.80M	$2.055M
YoY Change	242.22%	119.25%	-27.29%
% of Gross Profit	267.84%	244.63%	273.02%
Research & Development	$541.6K	$1.152M	$80.00K
YoY Change	577.04%	284.77%	31.41%
% of Gross Profit	20.63%	15.84%	10.63%
Depreciation & Amortization	$1.064M	$1.154K	$184.5K
YoY Change	476.84%	-99.83%	-61.39%
% of Gross Profit	40.52%	0.02%	24.5%
Operating Expenses	$8.639M	$24.22M	$2.319M
YoY Change	272.56%	166.07%	-31.1%
Operating Profit	-$6.013M	-$16.94M	-$1.566M
YoY Change	283.96%	151.47%	-46.79%
Interest Expense	$51.09K	$1.152M	-$6.859M
YoY Change	-100.74%	284.77%	-6091.59%
% of Operating Profit
Other Income/Expense, Net	$29.19K	$610.3K	$0.00
YoY Change		-105.93%
Pretax Income	-$5.933M	-$24.93K	-$8.048M
YoY Change	-26.29%	-93.37%	-1.28%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$5.933M	-$16.33M	-$8.048M
YoY Change	-26.29%	-4.12%	-1.28%
Net Earnings / Revenue	-70.79%	-73.63%	-343.34%
Basic Earnings Per Share
Diluted Earnings Per Share	-$408.3K	-$1.899M	-$3.764M
COMMON SHARES
Basic Shares Outstanding	14.39M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.584M	$2.584M	$101.3K
YoY Change	2450.14%	2450.14%	-71.13%
Cash & Equivalents	$2.584M		$99.91K
Short-Term Investments	$0.00	$0.00	$1.420K
Other Short-Term Assets	$546.1K	$546.1K	$167.1K
YoY Change	226.9%	226.9%	69.59%
Inventory
Prepaid Expenses	$175.3K		$140.5K
Receivables	$5.651M	$5.700M	$942.8K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$8.830M	$8.830M	$1.252M
YoY Change	605.07%	605.07%	-4.69%
LONG-TERM ASSETS
Property, Plant & Equipment	$481.00	$480.00	$1.635K
YoY Change	-70.58%	-99.66%	-99.25%
Goodwill	$7.719M		$3.517M
YoY Change	119.45%		0.0%
Intangibles	$9.742M		$795.9K
YoY Change	1124.06%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$17.46M	$17.46M	$4.455M
YoY Change	291.91%	291.9%	-13.77%
TOTAL ASSETS
Total Short-Term Assets	$8.830M	$8.830M	$1.252M
Total Long-Term Assets	$17.46M	$17.46M	$4.455M
Total Assets	$26.29M	$26.29M	$5.708M
YoY Change	360.62%	360.62%	-11.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.122M	$1.285M	$616.4K
YoY Change	81.94%	-7.96%	-57.41%
Accrued Expenses	$2.938M	$2.938M	$1.464M
YoY Change	100.73%	100.73%	-44.29%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$1.906M
YoY Change	-100.0%	-100.0%
Long-Term Debt Due	$1.712M	$1.712M	$28.25K
YoY Change	5961.56%	5961.56%	8.95%
Total Short-Term Liabilities	$7.563M	$7.563M	$16.69M
YoY Change	-54.69%	-54.69%	200.92%
LONG-TERM LIABILITIES
Long-Term Debt	$2.638M	$2.638M	$73.54K
YoY Change	3487.0%	3487.0%	-5.56%
Other Long-Term Liabilities	$0.00	$0.00	$67.26K
YoY Change	-100.0%	-100.0%	-52.18%
Total Long-Term Liabilities	$2.638M	$2.638M	$140.8K
YoY Change	1773.49%	1773.49%	-35.56%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.563M	$7.563M	$16.69M
Total Long-Term Liabilities	$2.638M	$2.638M	$140.8K
Total Liabilities	$10.20M	$10.20M	$16.83M
YoY Change	-39.4%	-39.4%	191.96%
SHAREHOLDERS EQUITY
Retained Earnings	-$50.86M		-$34.53M
YoY Change	47.31%
Common Stock	$1.457K		$220.00
YoY Change	562.27%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$16.09M	$16.09M	-$11.12M
YoY Change
Total Liabilities & Shareholders Equity	$26.29M	$26.29M	$5.708M
YoY Change	360.62%	360.62%	-11.93%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	-$5.933M	-$16.33M	-$8.048M
YoY Change	-26.29%	-4.12%	-1.28%
Depreciation, Depletion And Amortization	$1.064M	$1.154K	$184.5K
YoY Change	476.84%	-99.83%	-61.39%
Cash From Operating Activities	-$2.030M	-$9.016M	-$599.6K
YoY Change	238.56%	256.89%	-23.86%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$0.00
YoY Change		-100.0%
Acquisitions		$2.239M
YoY Change
Other Investing Activities	-$165.3K	-$2.239M	$0.00
YoY Change		-13262.61%	-100.0%
Cash From Investing Activities	-$165.3K	-$2.239M	$0.00
YoY Change		6686.57%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-567.5K	$13.74M	118.0K
YoY Change	-580.79%	483.93%	-69.81%
NET CHANGE
Cash From Operating Activities	-2.030M	-$9.016M	-599.6K
Cash From Investing Activities	-165.3K	-$2.239M	0.000
Cash From Financing Activities	-567.5K	$13.74M	118.0K
Net Change In Cash	-2.763M	$2.484M	-481.6K
YoY Change	473.71%	-1303.88%	30.33%
FREE CASH FLOW
Cash From Operating Activities	-$2.030M	-$9.016M	-$599.6K
Capital Expenditures	$0.00	$0.00	$0.00
Free Cash Flow	-$2.030M	-$9.016M	-$599.6K
YoY Change	238.56%	264.1%	-23.86%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	942842	USD
CY2021Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	49033	USD
CY2020Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	41124	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	546079	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	167045	USD
CY2021Q4	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	0	USD
CY2020Q4	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	1424	USD
CY2021	dei	Auditor Location AuditorLocation	Boca Raton, Florida
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2584062	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	99906	USD
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	934219	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	33000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5650668	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	8829842	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	1252341	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2982	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1828	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	481	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1635	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	140642	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	9741832	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	795864	USD
CY2021Q4	us-gaap	Goodwill Goodwill	7718842	USD
CY2020Q4	us-gaap	Goodwill Goodwill	3517315	USD
CY2021Q4	us-gaap	Assets Assets	26290997	USD
CY2020Q4	us-gaap	Assets Assets	5707797	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1121510	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	616421	USD
CY2021Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	163672	USD
CY2020Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	779928	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1285339	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	423237	USD
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities AccountsPayableAndOtherAccruedLiabilities	0	USD
CY2020Q4	us-gaap	Accounts Payable And Other Accrued Liabilities AccountsPayableAndOtherAccruedLiabilities	8000	USD
CY2021Q4	rcrt	Accrued Compensation AccruedCompensation	1551162	USD
CY2020Q4	rcrt	Accrued Compensation AccruedCompensation	617067	USD
CY2021Q4	rcrt	Accrued Compensation Related Party AccruedCompensationRelatedParty	0	USD
CY2020Q4	rcrt	Accrued Compensation Related Party AccruedCompensationRelatedParty	122500	USD
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	19726	USD
CY2020Q4	us-gaap	Interest Payable Current InterestPayableCurrent	60404	USD
CY2021Q4	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	578591	USD
CY2020Q4	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	0	USD
CY2021Q4	rcrt	Liability On Sale Of Future Revenues Net Of Discount LiabilityOnSaleOfFutureRevenuesNetOfDiscount	0	USD
CY2020Q4	rcrt	Liability On Sale Of Future Revenues Net Of Discount LiabilityOnSaleOfFutureRevenuesNetOfDiscount	2719	USD
CY2021Q4	rcrt	Sale On Liability Future Revenues Net Discount SaleOnLiabilityFutureRevenuesNetDiscount	0	USD
CY2020Q4	rcrt	Sale On Liability Future Revenues Net Discount SaleOnLiabilityFutureRevenuesNetDiscount	8185	USD
CY2021Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	81728	USD
CY2020Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	159032	USD
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	17333	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	14493	USD
CY2021Q4	us-gaap	Loans Payable Current LoansPayableCurrent	1712387	USD
CY2020Q4	us-gaap	Loans Payable Current LoansPayableCurrent	28249	USD
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	0	USD
CY2020Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	1205699	USD
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	0	USD
CY2020Q4	us-gaap	Notes Payable Current NotesPayableCurrent	1905826	USD
CY2021Q4	rcrt	Refundable Deposit On Preferred Stock Purchases RefundableDepositOnPreferredStockPurchases	285000	USD
CY2020Q4	rcrt	Refundable Deposit On Preferred Stock Purchases RefundableDepositOnPreferredStockPurchases	285000	USD
CY2021Q4	rcrt	Warrant Derivative Liability WarrantDerivativeLiability	0	USD
CY2020Q4	rcrt	Warrant Derivative Liability WarrantDerivativeLiability	11537997	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	73378	USD
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	746449	USD
CY2020Q4	us-gaap	Deferred Revenue DeferredRevenue	51537	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7562897	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16691254	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	67264	USD
CY2021Q4	us-gaap	Long Term Notes And Loans LongTermNotesAndLoans	2637875	USD
CY2020Q4	us-gaap	Long Term Notes And Loans LongTermNotesAndLoans	73541	USD
CY2021Q4	us-gaap	Liabilities Liabilities	10200772	USD
CY2020Q4	us-gaap	Liabilities Liabilities	16832059	USD
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14566420	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2201604	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	1457	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	220	USD
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	587945	shares
CY2020Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	0	shares
CY2021Q4	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	59	USD
CY2020Q4	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	0	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	66948340	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	23400408	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-50859640	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-34525025	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	16090225	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-11124262	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	26290997	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5707797	USD
CY2021	us-gaap	Revenues Revenues	22184112	USD
CY2020	us-gaap	Revenues Revenues	8502892	USD
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	14909389	USD
CY2020	us-gaap	Cost Of Revenue CostOfRevenue	6138363	USD
CY2021	us-gaap	Gross Profit GrossProfit	7274723	USD
CY2020	us-gaap	Gross Profit GrossProfit	2364529	USD
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	472213	USD
CY2020	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	82904	USD
CY2021	us-gaap	Interest Expense InterestExpense	1152433	USD
CY2020	us-gaap	Interest Expense InterestExpense	299512	USD
CY2021	rcrt	Amortization Of Intangibles AmortizationOfIntangibles	2741008	USD
CY2020	rcrt	Amortization Of Intangibles AmortizationOfIntangibles	686691	USD
CY2021	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	2530325	USD
CY2020	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	0	USD
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17323695	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8033685	USD
CY2021	us-gaap	Operating Expenses OperatingExpenses	24219674	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	9102792	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-16944951	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-6738263	USD
CY2021	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	3137050	USD
CY2020	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	2022113	USD
CY2021	rcrt	Initial Derivative Expense InitialDerivativeExpense	-3585983	USD
CY2020	rcrt	Initial Derivative Expense InitialDerivativeExpense	-3340554	USD
CY2021	rcrt	Change In Derivative Value Due To Antidilution Modification ChangeInDerivativeValueDueToAntidilutionModification	0	USD
CY2020	rcrt	Change In Derivative Value Due To Antidilution Modification ChangeInDerivativeValueDueToAntidilutionModification	-2642175	USD
CY2021	rcrt	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities	-7315580	USD
CY2020	rcrt	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities	2658261	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-24925	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-376177	USD
CY2021	rcrt	Grant Income GrantIncome	-3382	USD
CY2020	rcrt	Grant Income GrantIncome	-10768	USD
CY2021	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	1424	USD
CY2020	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	22416	USD
CY2021	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	9094	USD
CY2020	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	0	USD
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	610336	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-10298574	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-16334615	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-17036837	USD
CY2021	us-gaap	Profit Loss ProfitLoss	-16334615	USD
CY2020	us-gaap	Profit Loss ProfitLoss	-17036837	USD
CY2021	rcrt	Net Loss Per Common Share Basic And Diluted NetLossPerCommonShareBasicAndDiluted	1.90
CY2020	rcrt	Net Loss Per Common Share Basic And Diluted NetLossPerCommonShareBasicAndDiluted	8.75
CY2021	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	8601159	shares
CY2020	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	1949463	shares
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	715356	USD
CY2020	rcrt	Stock Based Compensation StockBasedCompensation	3058072	USD
CY2020	rcrt	Series D Preferred Stock Issued For Accrued Penalties Amount SeriesDPreferredStockIssuedForAccruedPenaltiesAmount	1929516	USD
CY2020	rcrt	Issuance Of Common Shares Upon Conversion Of Series D Preferred Stock Amount IssuanceOfCommonSharesUponConversionOfSeriesDPreferredStockAmount	0	USD
CY2020	rcrt	Issuance Of Common Shares Upon Conversion Of Series E Preferred Stock Amount IssuanceOfCommonSharesUponConversionOfSeriesEPreferredStockAmount	0	USD
CY2020	rcrt	Issuance Of Common Shares Upon Conversion Of Series F Preferred Stock Amount IssuanceOfCommonSharesUponConversionOfSeriesFPreferredStockAmount	0	USD
CY2020	rcrt	Sale Of Series D Preferred Stock Units Amount SaleOfSeriesDPreferredStockUnitsAmount	25000	USD
CY2020	rcrt	Reclassification Of Warrant Derivative To Liabilities Related To Series D Unit Sale ReclassificationOfWarrantDerivativeToLiabilitiesRelatedToSeriesDUnitSale	-26465	USD
CY2020	rcrt	Issuance Of Shares For Services Amount IssuanceOfSharesForServicesAmount	154700	USD
CY2020	rcrt	Issuance Of Vested Shares Amount IssuanceOfVestedSharesAmount	0	USD
CY2020	rcrt	Issuance Of Common Shares Upon Conversion Of Convertible Notes And Accrued Interest Amount IssuanceOfCommonSharesUponConversionOfConvertibleNotesAndAccruedInterestAmount	56396	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-17036837	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-11124262	USD
CY2021	rcrt	Stock Based Compensation StockBasedCompensation	5119118	USD
CY2021	rcrt	Issuance Of Common Shares For Scouted Amount IssuanceOfCommonSharesForScoutedAmount	1625184	USD
CY2021	rcrt	Issuance Of Initial And Earnout Shares For Upsider Acquisition Amount IssuanceOfInitialAndEarnoutSharesForUpsiderAcquisitionAmount	3460334	USD
CY2021	rcrt	Issuance Of Common Shares For Accrued Compensation Amount IssuanceOfCommonSharesForAccruedCompensationAmount	16425	USD
CY2021	rcrt	Issuance Of Common Shares Upon Conversion Of Debentures And Accrued Interest Amount IssuanceOfCommonSharesUponConversionOfDebenturesAndAccruedInterestAmount	4557718	USD
CY2021	rcrt	Cancellation Of Series D Preferred Stock Amount CancellationOfSeriesDPreferredStockAmount	0	USD
CY2021	rcrt	Reclassification Of Warrant Derivative To Liabilities Related To Series D Unit Sales1 ReclassificationOfWarrantDerivativeToLiabilitiesRelatedToSeriesDUnitSales1	10182476	USD
CY2021	rcrt	Issuance Of Common Shares And Pre Funded Warrants Upon Conversion Of Series D Preferred Stock Amount IssuanceOfCommonSharesAndPreFundedWarrantsUponConversionOfSeriesDPreferredStockAmount	0	USD
CY2021	rcrt	Issuance Of Common Shares Upon Conversion Of Series F Preferred Stock Amount IssuanceOfCommonSharesUponConversionOfSeriesFPreferredStockAmount	0	USD
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1436777	USD
CY2021	rcrt	Issuance Of Shares For Services Amount IssuanceOfSharesForServicesAmount	519239	USD
CY2021	rcrt	Issuance Of Common Shares For Accounts Payable Amount IssuanceOfCommonSharesForAccountsPayableAmount	140000	USD
CY2021	rcrt	Proceeds From Sale Of Common Stock And Warrants In Offering Amount ProceedsFromSaleOfCommonStockAndWarrantsInOfferingAmount	12003600	USD
CY2021	rcrt	Cost Related To Increase In Debenture Warrants CostRelatedToIncreaseInDebentureWarrants	12624	USD
CY2021	rcrt	Deferred Offering Costs Amount DeferredOfferingCostsAmount	-78038	USD
CY2021	rcrt	Common Stock Issued For The Exercises Of Warrants Shares Amount CommonStockIssuedForTheExercisesOfWarrantsSharesAmount	0	USD
CY2021	rcrt	Issuance Of Common Shares Upon Conversion Of Series E Preferred Stock Amount IssuanceOfCommonSharesUponConversionOfSeriesEPreferredStockAmount	0	USD
CY2021	rcrt	Issuance Of Common Shares For Parrut Acquisition Amount IssuanceOfCommonSharesForParrutAcquisitionAmount	1264551	USD
CY2021	rcrt	Issuance Of Common Shares For Novo Acquisition Amount IssuanceOfCommonSharesForNovoAcquisitionAmount	2019583	USD
CY2021	rcrt	Proceeds From Sale Of Common Stock Related To Over Allotment Offering Amount ProceedsFromSaleOfCommonStockRelatedToOverAllotmentOfferingAmount	1796400	USD
CY2021	us-gaap	Payments For Previous Acquisition PaymentsForPreviousAcquisition	1125000	USD
CY2021	rcrt	Rsus Issued Amount RsusIssuedAmount	0	USD
CY2021	rcrt	Fractional Shares Issued From Stock Split Amount FractionalSharesIssuedFromStockSplitAmount	0	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-16334615	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	16090225	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-16334615	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-17036837	USD
CY2021	us-gaap	Depreciation Nonproduction DepreciationNonproduction	2742162	USD
CY2020	us-gaap	Depreciation Nonproduction DepreciationNonproduction	687845	USD
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	927847	USD
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	12000	USD
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-24925	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-376177	USD
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5400975	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3212772	USD
CY2021	rcrt	Recognized Loss Gain On Marketable Securities RecognizedLossGainOnMarketableSecurities	1424	USD
CY2020	rcrt	Recognized Loss Gain On Marketable Securities RecognizedLossGainOnMarketableSecurities	22416	USD
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	USD
CY2020	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	3917	USD
CY2021	rcrt	Expenses Paid Through Financings ExpensesPaidThroughFinancings	0	USD
CY2020	rcrt	Expenses Paid Through Financings ExpensesPaidThroughFinancings	32500	USD
CY2021	rcrt	Loans Principal Paid Directly Through Grant LoansPrincipalPaidDirectlyThroughGrant	-2992	USD
CY2020	rcrt	Loans Principal Paid Directly Through Grant LoansPrincipalPaidDirectlyThroughGrant	-8853	USD
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	2503160	USD
CY2020	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1840745	USD
CY2021	us-gaap	Derivative Gain On Derivative DerivativeGainOnDerivative	12624	USD
CY2020	us-gaap	Derivative Gain On Derivative DerivativeGainOnDerivative	0	USD
CY2021	rcrt	Initial Derivative Expense Charged To Interest InitialDerivativeExpenseChargedToInterest	3585983	USD
CY2020	rcrt	Initial Derivative Expense Charged To Interest InitialDerivativeExpenseChargedToInterest	3340554	USD
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	USD
CY2020	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	2642175	USD
CY2021	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-7315580	USD
CY2020	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	2658261	USD
CY2021	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	2530325	USD
CY2020	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	0	USD
CY2021	us-gaap	Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	35294	USD
CY2020	us-gaap	Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	0	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-4690668	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-94767	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	-7909	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	-36784	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-74742	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-68542	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1991446	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	626895	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-746756	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-63863	USD
CY2021	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-77304	USD
CY2020	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	0	USD
CY2021	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	2840	USD
CY2020	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	173525	USD
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	525767	USD
CY2020	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-93937	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9015644	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2526155	USD
CY2021	us-gaap	Proceeds From Sale Of Held To Maturity Securities ProceedsFromSaleOfHeldToMaturitySecurities	0	USD
CY2020	us-gaap	Proceeds From Sale Of Held To Maturity Securities ProceedsFromSaleOfHeldToMaturitySecurities	17009	USD
CY2021	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	2238958	USD
CY2020	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	0	USD
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
CY2020	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	50000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2238958	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-32991	USD
CY2021	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	250000	USD
CY2020	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	398545	USD
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	2153200	USD
CY2020	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	2476000	USD
CY2021	rcrt	Deferred Offering Cost DeferredOfferingCost	-78038	USD
CY2020	rcrt	Deferred Offering Cost DeferredOfferingCost	0	USD
CY2021	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-723611	USD
CY2020	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-17907	USD
CY2021	rcrt	Advances On Receivables AdvancesOnReceivables	0	USD
CY2020	rcrt	Advances On Receivables AdvancesOnReceivables	180778	USD
CY2021	us-gaap	Repayments Of Accounts Receivable Securitization RepaymentsOfAccountsReceivableSecuritization	0	USD
CY2020	us-gaap	Repayments Of Accounts Receivable Securitization RepaymentsOfAccountsReceivableSecuritization	180778	USD
CY2021	rcrt	Repayments Of Receivables Sale RepaymentsOfReceivablesSale	-10904	USD
CY2020	rcrt	Repayments Of Receivables Sale RepaymentsOfReceivablesSale	-528838	USD
CY2021	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	13800000	shares
CY2021	rcrt	Offering Costs OfferingCosts	-1651889	USD
CY2020	rcrt	Offering Costs OfferingCosts	0	USD
CY2021	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	25000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13738758	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2352800	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	2484156	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-206346	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	99906	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	306252	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2584062	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	99906	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	240980	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	235813	USD
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2021	rcrt	Original Issue Discount Deducted From Convertible Note Proceeds OriginalIssueDiscountDeductedFromConvertibleNoteProceeds	342554	USD
CY2020	rcrt	Original Issue Discount Deducted From Convertible Note Proceeds OriginalIssueDiscountDeductedFromConvertibleNoteProceeds	328125	USD
CY2021	rcrt	Debt Costs Deducted From Convertible Note Proceeds DebtCostsDeductedFromConvertibleNoteProceeds	334800	USD
CY2020	rcrt	Debt Costs Deducted From Convertible Note Proceeds DebtCostsDeductedFromConvertibleNoteProceeds	366500	USD
CY2021	rcrt	Notes And Accrued Interest Converted To Common Stock NotesAndAccruedInterestConvertedToCommonStock	4557718	USD
CY2020	rcrt	Notes And Accrued Interest Converted To Common Stock NotesAndAccruedInterestConvertedToCommonStock	96000	USD
CY2021	rcrt	Notes Payable And Accrued Interest Exchanged For Debentures NotesPayableAndAccruedInterestExchangedForDebentures	252430	USD
CY2020	rcrt	Notes Payable And Accrued Interest Exchanged For Debentures NotesPayableAndAccruedInterestExchangedForDebentures	0	USD
CY2021	rcrt	Accounts Payable Paid With Common Stock AccountsPayablePaidWithCommonStock	140000	USD
CY2020	rcrt	Accounts Payable Paid With Common Stock AccountsPayablePaidWithCommonStock	0	USD
CY2021	rcrt	Accrued Compensation Paid With Common Stock AccruedCompensationPaidWithCommonStock	16425	USD
CY2020	rcrt	Accrued Compensation Paid With Common Stock AccruedCompensationPaidWithCommonStock	0	USD
CY2021	rcrt	Warrant Derivative Liability Extinguished WarrantDerivativeLiabilityExtinguished	10182476	USD
CY2020	rcrt	Warrant Derivative Liability Extinguished WarrantDerivativeLiabilityExtinguished	0	USD
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	103953	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	78038	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	0	USD
CY2021	rcrt	Common Stock Issuedto Be Issued For Asset Acquisitions CommonStockIssuedtoBeIssuedForAssetAcquisitions	11340284	USD
CY2020	rcrt	Common Stock Issuedto Be Issued For Asset Acquisitions CommonStockIssuedtoBeIssuedForAssetAcquisitions	0	USD
CY2021	rcrt	Earn Out Liability Consideration For Acquisition EarnOutLiabilityConsiderationForAcquisition	543297	USD
CY2020	rcrt	Earn Out Liability Consideration For Acquisition EarnOutLiabilityConsiderationForAcquisition	0	USD
CY2021	rcrt	Common Stock Issued To Be Issued For Asset Acquisitions CommonStockIssuedToBeIssuedForAssetAcquisitions	4750000	USD
CY2020	rcrt	Common Stock Issued To Be Issued For Asset Acquisitions CommonStockIssuedToBeIssuedForAssetAcquisitions	0	USD
CY2021	rcrt	Shares Issued For Upsider Earn Out Liability SharesIssuedForUpsiderEarnOutLiability	1394768	USD
CY2020	rcrt	Shares Issued For Upsider Earn Out Liability SharesIssuedForUpsiderEarnOutLiability	0	USD
CY2021	rcrt	Preferred Stock Issued For Accrued Penalties PreferredStockIssuedForAccruedPenalties	0	USD
CY2020	rcrt	Preferred Stock Issued For Accrued Penalties PreferredStockIssuedForAccruedPenalties	1929516	USD
CY2021	rcrt	Warrant Derivative Liability At Inception WarrantDerivativeLiabilityAtInception	2374076	USD
CY2020	rcrt	Warrant Derivative Liability At Inception WarrantDerivativeLiabilityAtInception	5625519	USD
CY2021	rcrt	Prepayment Of Shares Issued For Services PrepaymentOfSharesIssuedForServices	237382	USD
CY2020	rcrt	Prepayment Of Shares Issued For Services PrepaymentOfSharesIssuedForServices	0	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1960072	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-3905216	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-1164208	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	9741832	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	795864	USD
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2741008	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	686691	USD
CY2021	rcrt	Disrupt Recruiting Staff Expenses DisruptRecruitingStaffExpenses	136000000000	USD
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	31250000	shares
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results and outcomes may differ from management’s estimates and assumptions. Included in these estimates are assumptions used to estimate collection of accounts receivable, fair value of marketable securities, fair value of assets acquired and liabilities assumed in asset acquisitions and the estimated useful life of assets acquired, fair value of contingent consideration in asset acquisitions and business combinations, fair value of derivative liabilities, fair value of securities issued for acquisitions and business combinations, fair value of assets acquired and liabilities assumed in business combinations, fair value of intangible assets and goodwill, valuation of lease liabilities and related right of use assets, deferred income tax asset valuation allowances, and valuation of stock based compensation expense.</p>
CY2021Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	1667798	USD
CY2021	rcrt	Advertising And Marketing Costs AdvertisingAndMarketingCosts	472213	USD
CY2020	rcrt	Advertising And Marketing Costs AdvertisingAndMarketingCosts	82904	USD
CY2021	us-gaap	Revenues Revenues	22184112	USD
CY2020	us-gaap	Revenues Revenues	8502892	USD
CY2021Q4	rcrt	Deferred Revenues DeferredRevenues	746449	USD
CY2020Q4	rcrt	Deferred Revenues DeferredRevenues	51537	USD
CY2021	us-gaap	Deferred Revenue Additions DeferredRevenueAdditions	746449	USD
CY2021Q1	us-gaap	Deferred Revenue Additions DeferredRevenueAdditions	485113	USD
CY2021Q2	us-gaap	Deferred Revenue Additions DeferredRevenueAdditions	216233	USD
CY2021Q3	us-gaap	Deferred Revenue Additions DeferredRevenueAdditions	25079	USD
CY2021Q4	us-gaap	Deferred Revenue Additions DeferredRevenueAdditions	18550	USD
CY2020	us-gaap	Deferred Revenue Additions DeferredRevenueAdditions	1474	USD
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	934219	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	33000	USD
CY2020	rcrt	Bad Debt Expense BadDebtExpense	12000	USD
CY2021	us-gaap	Depreciation Depreciation	1154	USD
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	As of December 31, 2021, two customers accounted for more than 10% of the accounts receivable balance, at 14% and 12%, for a total of 26%. As of December 31, 2020, two customers accounted for more than 10% of the accounts receivable balance, at 32% and 19% for a total of 51%. <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">For the year ended December 31, 2021 one customer accounted for 10% or more of total revenue, at 12%. For the year ended December 31, 2020 three customers accounted for 10% of more of total revenue, at 30%, 20% and 11%, for a total of 61%.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We use a related party firm located overseas for software development and maintenance related to our website and the platform underlying our operations. One of our officers and principal shareholders is an employee of this firm but exerts control over this firm (see Note 13). </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We are a party to a license agreement with a related party firm (see Note 13). Pursuant to the license agreement the firm has granted us an exclusive license to use certain candidate matching software and render certain related services to us. If this relationship was terminated or if the firm was to cease doing business or cease to support the applications we currently utilize, we may be forced to expend significant time and resources to replace the licensed software. Further, the necessary replacements may not be available on a timely basis on favorable terms, or at all. If we were to lose the ability to use this software our business and operating results could be materially and adversely affected.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We use a related party firm to provide certain employer of record services (see Note 13).</p>
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Rolling Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths	3577824	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Two FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo	3418651	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Three FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree	1650353	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Four FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour	776867	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Five FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive	293001	USD
CY2021Q4	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	578591	USD
CY2020Q4	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	1424	USD
CY2020Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	11537997	USD
CY2021	rcrt	Balance At Beginning Of Period Of Derivative Liability BalanceAtBeginningOfPeriodOfDerivativeLiability	11537997	USD
CY2020	rcrt	Balance At Beginning Of Period Of Derivative Liability BalanceAtBeginningOfPeriodOfDerivativeLiability	612042	USD
CY2021	rcrt	Additionsto Derivative Instruments AdditionstoDerivativeInstruments	5960059	USD
CY2020	rcrt	Additionsto Derivative Instruments AdditionstoDerivativeInstruments	5625519	USD
CY2021	rcrt	Reclassification To Equity Upon Modification Or Cancellation Of Warrants ReclassificationToEquityUponModificationOrCancellationOfWarrants	-10182476	USD
CY2020	rcrt	Reclassification To Equity Upon Modification Or Cancellation Of Warrants ReclassificationToEquityUponModificationOrCancellationOfWarrants	2642175	USD
CY2021	rcrt	Gain Loss On Change In Fair Value Of Derivative Liability GainLossOnChangeInFairValueOfDerivativeLiability	-7315580	USD
CY2020	rcrt	Gain Loss On Change In Fair Value Of Derivative Liability GainLossOnChangeInFairValueOfDerivativeLiability	2658261	USD
CY2021	rcrt	Balance At End Of Period Derivativeliability BalanceAtEndOfPeriodDerivativeliability	0	USD
CY2020	rcrt	Balance At End Of Period Derivativeliability BalanceAtEndOfPeriodDerivativeliability	11537997	USD
CY2021	rcrt	Balance At Beginningliability Measured At Fair Value BalanceAtBeginningliabilityMeasuredAtFairValue	0	USD
CY2021	rcrt	Novo Group Acquisition Acquisitions And Settlements NovoGroupAcquisitionAcquisitionsAndSettlements	543297	USD
CY2021	rcrt	Gains Included In Interest Expense Remeasurement Adjustments GainsIncludedInInterestExpenseRemeasurementAdjustments	35294	USD
CY2021	rcrt	Balance At Endingliability Measured At Fair Value BalanceAtEndingliabilityMeasuredAtFairValue	578591	USD
CY2021Q4	rcrt	Fair Value Of Contingent Consideration Liabilities FairValueOfContingentConsiderationLiabilities	578591	USD
CY2021	rcrt	Valuation Technique ValuationTechnique	Discounted cash flow
CY2021	rcrt	Significant Unobservable Input SignificantUnobservableInput	Projected revenue and probability of achievement
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive	25136	USD
CY2020	rcrt	Goodwill Other GoodwillOther	3517315	USD
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	2530325	USD
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2021Q4	us-gaap	Goodwill Goodwill	7718842	USD
CY2020Q4	us-gaap	Goodwill Goodwill	3517315	USD
CY2021	us-gaap	Derivatives Reporting Of Derivative Activity DerivativesReportingOfDerivativeActivity	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In August 2020, the FASB issued ASU 2020-06, Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity. This ASU removes certain separation models in ASC 470-20 for convertible instruments, and, as a result, embedded conversion features that do not require bifurcation under ASC 815 are no longer subject to separation into an equity classified component. Consequently, a convertible debt instrument, shall be accounted for as a single liability measured at its amortized cost. The Company adopted ASU 2020-06 on January 1, 2021 using the modified retrospective transition method.</p>The Company’s derivative financial instruments consisted of derivatives related to the warrants issued with the sale of our convertible notes in 2020 and 2021 (see Note 9) and the warrants issued with the sale of our Series D Preferred Stock in 2020 and 2019 (see Note 9 and 10). The accounting treatment of derivative financial instruments requires that we record the derivatives at their fair values as of the inception date of the debt agreements and at fair value as of each subsequent balance sheet date. Any change in fair value is recorded as non-operating, non-cash income or expense at each balance sheet date. If the fair value of the derivatives was higher at the subsequent balance sheet date, we recorded a non-operating, non-cash charge. If the fair value of the derivatives was lower at the subsequent balance sheet date, we recorded non-operating, non-cash income. Upon the determination that an instrument is no longer subject to derivative accounting, the fair value of the derivative instrument at the date of such determination will be reclassified to paid-in capital. The entirety of our derivative financial instruments was eliminated in July 2021 upon conversion of certain outstanding warrants to common stock and agreement by investors to modify certain warrants to eliminate the feature creating the derivative liability in the remaining outstanding warrants (see Note 11).
CY2021	rcrt	Antidilutive Securities AntidilutiveSecurities	9668635	shares
CY2020	rcrt	Antidilutive Securities AntidilutiveSecurities	9709468	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9668635	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9709468	shares
CY2021Q4	rcrt	Prepaid Shares Issued For Services PrepaidSharesIssuedForServices	237382	USD
CY2020Q4	rcrt	Prepaid Shares Issued For Services PrepaidSharesIssuedForServices	0	USD
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	175263	USD
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	140514	USD
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	111040	USD
CY2020Q4	us-gaap	Prepaid Insurance PrepaidInsurance	26531	USD
CY2021Q4	us-gaap	Other Receivables OtherReceivables	22394	USD
CY2020Q4	us-gaap	Other Receivables OtherReceivables	0	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	546079	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	167045	USD
CY2021Q3	us-gaap	Available For Sale Securities And Held To Maturity Securities AvailableForSaleSecuritiesAndHeldToMaturitySecurities	42720	USD
CY2019Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangibles BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles	1910072	USD
CY2020Q3	us-gaap	Officers Compensation OfficersCompensation	50000	USD
CY2020Q3	us-gaap	Salaries And Wages SalariesAndWages	125000	USD
CY2020Q3	rcrt	Cost Of Contracts Acquired Amortized CostOfContractsAcquiredAmortized	50000	USD
CY2021	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	11600000	USD
CY2021	us-gaap	Available For Sale Equity Securities Gross Unrealized Loss AvailableForSaleEquitySecuritiesGrossUnrealizedLoss	42720	USD
CY2020	us-gaap	Available For Sale Equity Securities Gross Unrealized Loss AvailableForSaleEquitySecuritiesGrossUnrealizedLoss	41296	USD
CY2021Q3	us-gaap	Available For Sale Securities Equity Securities AvailableForSaleSecuritiesEquitySecurities	0	USD
CY2020Q4	us-gaap	Available For Sale Securities Equity Securities AvailableForSaleSecuritiesEquitySecurities	1424	USD
CY2021Q3	rcrt	Shares Owned In Marketable Securities SharesOwnedInMarketableSecurities	178000	shares
CY2021Q3	rcrt	Average Per Share Market Price AveragePerShareMarketPrice	0.00
CY2020Q4	rcrt	Average Per Share Market Price AveragePerShareMarketPrice	0.01
CY2021	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
CY2020	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-2543	USD
CY2021	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-1424	USD
CY2020	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-19873	USD
CY2021	rcrt	Total Marketable Securities Gain Loss TotalMarketableSecuritiesGainLoss	-1424	USD
CY2020	rcrt	Total Marketable Securities Gain Loss TotalMarketableSecuritiesGainLoss	-22416	USD
CY2020Q4	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	1424	USD
CY2019Q4	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	44766	USD
CY2021	rcrt	Marketable Securities Received As Payment For Series D Preferred Stock MarketableSecuritiesReceivedAsPaymentForSeriesDPreferredStock	0	USD
CY2020	rcrt	Marketable Securities Received As Payment For Series D Preferred Stock MarketableSecuritiesReceivedAsPaymentForSeriesDPreferredStock	0	USD
CY2021	rcrt	Proceeds On Sales Of Securities ProceedsOnSalesOfSecurities	0	USD
CY2020	rcrt	Proceeds On Sales Of Securities ProceedsOnSalesOfSecurities	17009	USD
CY2021	rcrt	Assignment Of Securities As Compensations AssignmentOfSecuritiesAsCompensations	0	USD
CY2020	rcrt	Assignment Of Securities As Compensations AssignmentOfSecuritiesAsCompensations	-3917	USD
CY2021	rcrt	Recognized Losses RecognizedLosses	-1424	USD
CY2020	rcrt	Recognized Losses RecognizedLosses	-22416	USD
CY2021Q4	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	0	USD
CY2020Q4	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	1424	USD
CY2021Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet	6731852	USD
CY2020Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet	3517315	USD
	rcrt	Impairment Expense ImpairmentExpense	2530325	USD
CY2020Q4	us-gaap	Goodwill Goodwill	3517315	USD
CY2019Q4	us-gaap	Goodwill Goodwill	3517315	USD
CY2021	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	6731852	USD
CY2020	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	0	USD
CY2021	rcrt	Goodwill Other GoodwillOther	10249167	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	13647048	USD
CY2021	rcrt	Repayments Paid RepaymentsPaid	567001	USD
CY2021	rcrt	Initial Discount InitialDiscount	142491	USD
CY2019Q4	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	2719	USD
CY2020	rcrt	Amortized Discount To Interest Expense AmortizedDiscountToInterestExpense	132922	USD
CY2020Q4	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	0	USD
CY2021	rcrt	Amortized Discount To Interest Expense AmortizedDiscountToInterestExpense	2719	USD
CY2021	rcrt	Outstanding Balance Of Debt OutstandingBalanceOfDebt	0	USD
CY2020	rcrt	Outstanding Balance Of Debt OutstandingBalanceOfDebt	10904	USD
CY2020Q1	rcrt	Advances Interest Rate Per Month AdvancesInterestRatePerMonth	0.015	pure
CY2020Q1	rcrt	Advances Received Under Agreement AdvancesReceivedUnderAgreement	180778	USD
CY2020Q4	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	0	USD
CY2020Q4	us-gaap	Line Of Credit Facility Capacity Available For Trade Purchases LineOfCreditFacilityCapacityAvailableForTradePurchases	91300	USD
CY2021Q1	rcrt	Small Business Payment SmallBusinessPayment	3382	USD
CY2021Q1	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	2992	USD
CY2021Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	390	USD
CY2020	rcrt	Small Business Payment SmallBusinessPayment	10768	USD
CY2020	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	8854	USD
CY2020	us-gaap	Interest Expense Debt InterestExpenseDebt	1914	USD
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	50431	USD
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	77040	USD
CY2020Q4	rcrt	Paycheck Protection Program Loan PaycheckProtectionProgramLoan	24750	USD
CY2021Q4	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	4299831	USD
CY2020Q4	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	0	USD
CY2021Q4	us-gaap	Notes Payable NotesPayable	4350262	USD
CY2020Q4	us-gaap	Notes Payable NotesPayable	101790	USD
CY2021Q4	rcrt	Less Current Portions LessCurrentPortions	-1712387	USD
CY2020Q4	rcrt	Less Current Portions LessCurrentPortions	-28249	USD
CY2021Q4	us-gaap	Notes And Loans Payable NotesAndLoansPayable	2637875	USD
CY2020Q4	us-gaap	Notes And Loans Payable NotesAndLoansPayable	73541	USD
CY2021Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.00
CY2020Q4	rcrt	Unamortized Discount UnamortizedDiscount	1205699	USD
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	86000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1324022	shares
CY2020Q2	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	62800	shares
CY2020Q2	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	12560	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14566420	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2201604	shares
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q3	rcrt	Stock Unit Issue StockUnitIssue	2400000	shares
CY2021Q3	rcrt	Stock Unit Price Per Share StockUnitPricePerShare	5.00
CY2021Q3	rcrt	Stock Unit Issue StockUnitIssue	360000	shares
CY2021Q3	rcrt	Stock Unit Price Per Share StockUnitPricePerShare	5.00
CY2021	rcrt	Proceed From Underwritten Public Offering Amount ProceedFromUnderwrittenPublicOfferingAmount	13800000	USD
CY2020Q1	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	15704	shares
CY2020Q1	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	3141	shares
CY2020Q1	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	321366	shares
CY2020Q2	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	55570	shares
CY2020Q2	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	11114	shares
CY2020Q3	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	44000	shares
CY2020Q3	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	8800	shares
CY2021Q1	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	106876	shares
CY2021Q2	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	40000	shares
CY2021Q3	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	3229225	shares
CY2021Q3	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	645845	shares
CY2020Q4	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	24000	shares
CY2020Q4	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	91600	USD
CY2020Q4	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	4400	USD
CY2021	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	89172	shares
CY2021	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	354387	shares
CY2021	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	2302	USD
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1489444	shares
CY2021Q3	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	115593	USD
CY2021Q3	rcrt	Penalty Amount PenaltyAmount	253767	USD
CY2021Q3	rcrt	Unamortized Discount UnamortizedDiscount	1666314	USD
CY2021Q3	rcrt	Additional Paid In Capitals AdditionalPaidInCapitals	4291102	USD
CY2021Q4	rcrt	Stock Unit Issue StockUnitIssue	224163	shares
CY2021Q1	rcrt	Stock Unit Issue StockUnitIssue	271153	shares
CY2021Q2	rcrt	Stock Unit Issue StockUnitIssue	155327	shares
CY2021Q3	rcrt	Stock Unit Issue StockUnitIssue	257545	shares
CY2021Q3	rcrt	Stock Unit Issue StockUnitIssue	508711	shares
CY2021Q3	rcrt	Stock Unit Issue StockUnitIssue	321390	shares
CY2020Q4	rcrt	Stock Unit Issued StockUnitIssued	190000	shares
CY2020Q2	rcrt	Stock Unit Issued StockUnitIssued	1108000	shares
CY2017Q4	rcrt	Stock Unit Issued StockUnitIssued	2700000	shares
CY2021Q4	rcrt	Stock Unit Issued StockUnitIssued	3427946	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.10	pure
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	1.10	pure
CY2020Q3	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	100000	USD
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	20000	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6.75
CY2021Q1	rcrt	Sharebased Compensation Arrangement By Sharebased Payment Award At The Time Of Grant SharebasedCompensationArrangementBySharebasedPaymentAwardAtTheTimeOfGrant	134986	USD
CY2021Q1	rcrt	Compensation Expense Over Vesting Period CompensationExpenseOverVestingPeriod	11249	USD
CY2021Q1	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	17549	USD
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	3.54	pure
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.008	pure
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	159000	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.625
CY2021Q1	rcrt	Sharebased Compensation Arrangement By Sharebased Payment Award At The Time Of Grant SharebasedCompensationArrangementBySharebasedPaymentAwardAtTheTimeOfGrant	1371231	USD
CY2021Q1	rcrt	Compensation Expense Over Vesting Period CompensationExpenseOverVestingPeriod	342808	USD
CY2021Q1	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	428510	USD
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	3.46	pure
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.008	pure
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	20000	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.125
CY2021Q1	rcrt	Sharebased Compensation Arrangement By Sharebased Payment Award At The Time Of Grant SharebasedCompensationArrangementBySharebasedPaymentAwardAtTheTimeOfGrant	162491	USD
CY2021Q1	rcrt	Compensation Expense Over Vesting Period CompensationExpenseOverVestingPeriod	13541	USD
CY2021Q1	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	14669	USD
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	3.59	pure
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0083	pure
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	11800	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.125
CY2021Q2	rcrt	Compensation Expense Over Vesting Period CompensationExpenseOverVestingPeriod	95925	USD
CY2021Q2	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	15988	USD
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	3.50	pure
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.008	pure
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	12000	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.125
CY2021Q2	rcrt	Compensation Expense Over Vesting Period CompensationExpenseOverVestingPeriod	97551	USD
CY2021Q2	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	8129	USD
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	3.50	pure
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.008	pure
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	16600	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.125
CY2021Q2	rcrt	Compensation Expense Over Vesting Period CompensationExpenseOverVestingPeriod	134946	USD
CY2021Q2	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	22491	USD
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	3.50	pure
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.008	pure
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	8800	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.125
CY2021Q2	rcrt	Compensation Expense Over Vesting Period CompensationExpenseOverVestingPeriod	71538	USD
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	3.50	pure
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.008	pure
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	29000	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.50
CY2021Q2	rcrt	Compensation Expense Over Vesting Period CompensationExpenseOverVestingPeriod	65315	USD
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.35	pure
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0007	pure
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P1Y
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	110000	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.96
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights	The options will vest quarterly over two years, with the first portion vesting on October 8, 2021
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	25050	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.96
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights	The options will vest quarterly over four years, with a one year cliff, with the first portion vesting on August 26, 2022
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	35000	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.05
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights	The options vested 50% after 60 days and 50% after 180 days, with the first portion having vested on October 31, 2021
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	10000	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.05
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights	The options will vest quarterly over two years, with the first portion vesting on November 30, 2021
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	25000	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.05
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights	The options will vest quarterly over four years, with a one year cliff, with the first portion vesting on August 31, 2022
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	300000	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.65
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights	The options vested 25% at grant date on September 1, 2021 and 75% on March 1, 2023
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	100000	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.65
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights	The options were vested at grant date on September 6, 2022
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	7500	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.96
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights	The options will vest quarterly over two years, with the first portion vesting on December10, 2021
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	349000	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.96
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights	The options will vest quarterly over two years, with a one year cliff, with the first portion vesting on September 10, 2022
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	274500	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.96
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights	The options will vest quarterly over four years, with the first portion vesting on December 10, 2021
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	200000	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.59
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights	The options will vest quarterly over two years, with a one year cliff, with the first portion vesting on September 10, 2022
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	50000	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.97
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights	The options will vest quarterly over four years, with the first portion vesting on December 13, 2021
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	90000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.45
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	43900	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.45
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights	The options will vest quarterly over four years, with the first portion vesting on January 3, 2022.
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	100000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.45
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights	The options will vest monthly over two years, with an eighth of the options vesting immediately.
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	72500	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.96
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	7500	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.31
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights	The options will vest quarterly over four years, with the first portion vesting on February 23, 2022.
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	242850	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.86
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights	The options will vest quarterly over four years, with a one year cliff, with the first portion vesting on October 28, 2022.
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	35000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.60
CY2021Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.96
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights	The options will vest quarterly over four years, with the first portion vesting on March 10, 2022.
CY2021	rcrt	Stock Based Compensation Expenses StockBasedCompensationExpenses	4257434	USD
CY2020	rcrt	Stock Based Compensation Expenses StockBasedCompensationExpenses	2154457	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0007	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0133	pure
CY2021	rcrt	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term Maximum SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTermMaximum	P1Y
CY2021	rcrt	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term Minimum SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTermMinimum	P5Y
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.36	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	3.47	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2021	rcrt	Unrecognized Compensation Cost UnrecognizedCompensationCost	5724845	USD
CY2021Q4	rcrt	Non Vested Stock Options Periods Next Year NonVestedStockOptionsPeriodsNextYear	2988754	USD
CY2021Q4	rcrt	Non Vested Stock Options Periods Two Year NonVestedStockOptionsPeriodsTwoYear	1596575	USD
CY2021Q4	rcrt	Non Vested Stock Options Periods Three Year NonVestedStockOptionsPeriodsThreeYear	652168	USD
CY2021Q4	rcrt	Non Vested Stock Options Periods Four Year NonVestedStockOptionsPeriodsFourYear	487348	USD
CY2021Q4	rcrt	Intrinsic Value Of Options Outstanding IntrinsicValueOfOptionsOutstanding	53670	USD
CY2021Q4	rcrt	Intrinsic Value Of Options Exercisable IntrinsicValueOfOptionsExercisable	53670	USD
CY2021	rcrt	Placement Agent Warrants Description PlacementAgentWarrantsDescription	On January 5, 2021 and January 20, 2021, the Company issued 28,125 and 111,825 three year term common stock warrants respectively for a total of 139,950 warrants with an exercise price of $5.00. On July 2, 2021, the 139,950 warrants were reduced to 36,364 with an exercise price of $6.25. See "Convertible Debenture Warrants and Placement Agent Warrants” below
CY2021Q1	rcrt	Note Holder Warrants Description NoteHolderWarrantsDescription	On January 5, 2021, January 20, 2021 and February 3, 2021, the Company issued 140,625, 559,125, and 70,996 three year term common stock warrants respectively for a total of 770,746 warrants with an exercise price of $5.00. On July 2, 2021, the 770,746 warrants were increased to 772,303 with an exercise price of $5.00. See "Convertible Debenture Warrants and Placement Agent Warrants” below
CY2021Q3	rcrt	Stock Unit Issued StockUnitIssued	2400000	shares
CY2021Q3	rcrt	Stock Unit Price Per Share StockUnitPricePerShare	5.00
CY2021	rcrt	Proceeds From Underwritten Public Offering ProceedsFromUnderwrittenPublicOffering	12000000	USD
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.50
CY2021Q3	rcrt	Stock Unit Issued StockUnitIssued	360000	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.99
CY2021Q3	rcrt	Representative Warrants RepresentativeWarrants	240000	shares
CY2021Q3	rcrt	Representative Warrants Price Per Share RepresentativeWarrantsPricePerShare	6.25
CY2021Q3	rcrt	Warrants Upon Conversion Of Convertible Debentures Description WarrantsUponConversionOfConvertibleDebenturesDescription	On July 2, 2021, the Company issued 1,489,596 common stock warrants with an exercise price of $5.50 in conjunction with the conversion of all $5,588,359 of convertible debentures outstanding, $115,593 of accrued interest through July 2, 2021 and a penalty amount of $253,767 on the convertible debentures issued in May/September 2020 (as discussed previously in Note 10 under Common Stock)
CY2021Q2	rcrt	Warrants For Service Issued Shares WarrantsForServiceIssuedShares	20000	shares
CY2021Q2	rcrt	Warrants For Service Exercise Price WarrantsForServiceExercisePrice	5
CY2021	us-gaap	Interest Expense Other InterestExpenseOther	211614	USD
CY2021	us-gaap	Other Income OtherIncome	1886212	USD
CY2021	rcrt	Series D Warrants Exchanged Shares SeriesDWarrantsExchangedShares	522108	shares
CY2021Q4	rcrt	Derivative Liability DerivativeLiability	2404182	USD
CY2021	rcrt	Other Expense Related To The Change In The Fair Value Of The Derivative OtherExpenseRelatedToTheChangeInTheFairValueOfTheDerivative	676177	USD
CY2021	rcrt	Other Income Related To The Change In The Fair Value Of The Derivative OtherIncomeRelatedToTheChangeInTheFairValueOfTheDerivative	5429368	USD
CY2021Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	7405224	USD
CY2020	rcrt	Number Of Placement Agent Warrants Issued Reduced NumberOfPlacementAgentWarrantsIssuedReduced	287606	shares
CY2021	rcrt	Number Of Placement Agent Warrants Issued Reduced NumberOfPlacementAgentWarrantsIssuedReduced	36364	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	188376	shares
CY2019Q4	rcrt	Share Based Compensation Arrangement By Share Based Payment Award Warrants Outstanding Weighted Average Exercise Price Beginning Balance ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingWeightedAverageExercisePriceBeginningBalance	12.00
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	889376	shares
CY2020	rcrt	Share Based Compensation Arrangement By Share Based Payment Award Warrants Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsGrantsInPeriodWeightedAverageExercisePrice	5.03
CY2020	rcrt	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instrument Warrants Outstanding Cancelled Pursuant To Modification ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWarrantsOutstandingCancelledPursuantToModification	-191814	shares
CY2020	rcrt	Share Based Compensation Arrangement By Share Based Payment Award Warrants Weighted Average Price Per Share Cancelled Pursuant To Modification ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsWeightedAveragePricePerShareCancelledPursuantToModification	12.00
CY2020	rcrt	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instrument Warrants Outstanding Reissued Pursuant To Modification ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWarrantsOutstandingReissuedPursuantToModification	575440	shares
CY2020	rcrt	Share Based Compensation Arrangement By Share Based Payment Award Warrants Weighted Average Price Per Share Reissued Pursuant To Modification ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsWeightedAveragePricePerShareReissuedPursuantToModification	4.00
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	1461378	shares
CY2020Q4	rcrt	Share Based Compensation Arrangement By Share Based Payment Award Warrants Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingWeightedAverageExercisePrice	4.60
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	6008237	shares
CY2021	rcrt	Share Based Compensation Arrangement By Share Based Payment Award Warrants Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsGrantsInPeriodWeightedAverageExercisePrice	4.46
CY2021	rcrt	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instrument Warrants Outstanding Cancelled Pursuant To Modification ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWarrantsOutstandingCancelledPursuantToModification	-265148	shares
CY2021	rcrt	Share Based Compensation Arrangement By Share Based Payment Award Warrants Weighted Average Price Per Share Cancelled Pursuant To Modification ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsWeightedAveragePricePerShareCancelledPursuantToModification	1.92
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	522108	shares
CY2021	rcrt	Share Based Compensation Arrangement By Share Based Payment Award Warrants Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriodWeightedAverageExercisePrice	4.00
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	6682359	shares
CY2021Q4	rcrt	Share Based Compensation Arrangement By Share Based Payment Award Warrants Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingWeightedAverageExercisePrice	4.32
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y8M1D
CY2021Q4	us-gaap	Proceeds From Issuance Of Commercial Paper ProceedsFromIssuanceOfCommercialPaper	500000	USD
CY2021Q4	rcrt	Investor Relations Payment InvestorRelationsPayment	253505	USD
CY2021	us-gaap	Lease Cost LeaseCost	71014	USD
CY2021	us-gaap	Payments For Leasing Costs PaymentsForLeasingCosts	44526	USD
CY2021	rcrt	Base Lease Costs Amount BaseLeaseCostsAmount	26488	USD
CY2019Q1	rcrt	Lease Expiration Description LeaseExpirationDescription	The sublease expires in November 2022
CY2021	rcrt	Lease Payment Borrowing Rate LeasePaymentBorrowingRate	0.10	pure
CY2019Q1	rcrt	Operating Lease Right Of Use Asset Non Current OperatingLeaseRightOfUseAssetNonCurrent	269054	USD
CY2020	us-gaap	Lease Cost LeaseCost	150851	USD
CY2020	us-gaap	Payments For Leasing Costs PaymentsForLeasingCosts	86997	USD
CY2020	rcrt	Base Lease Costs Amount BaseLeaseCostsAmount	63854	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	0	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	269054	USD
CY2021Q4	rcrt	Less Accumulated Reduction LessAccumulatedReduction	0	USD
CY2020Q4	rcrt	Less Accumulated Reduction LessAccumulatedReduction	-128412	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	140642	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	0	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	269054	USD
CY2021Q4	us-gaap	Restructuring Reserve RestructuringReserve	0	USD
CY2020Q4	us-gaap	Restructuring Reserve RestructuringReserve	128412	USD
CY2021Q4	rcrt	Operating Lease Right Of Use Assets OperatingLeaseRightOfUseAssets	0	USD
CY2020Q4	rcrt	Operating Lease Right Of Use Assets OperatingLeaseRightOfUseAssets	140642	USD
CY2021Q4	rcrt	Operating Lease Liabilities Current OperatingLeaseLiabilitiesCurrent	0	USD
CY2020Q4	rcrt	Operating Lease Liabilities Current OperatingLeaseLiabilitiesCurrent	-73378	USD
CY2021Q4	rcrt	Operating Lease Liabilities Noncurrent OperatingLeaseLiabilitiesNoncurrent	0	USD
CY2020Q4	rcrt	Operating Lease Liabilities Noncurrent OperatingLeaseLiabilitiesNoncurrent	67264	USD
CY2020Q1	rcrt	Covid19 Description Covid19Description	The extent to which the COVID-19 pandemic will impact operations, ability to obtain financing or future financial results is uncertain at this time.
CY2019	rcrt	Description Of Consultant Agreement DescriptionOfConsultantAgreement	The Company has agreed to pay the consultant a retainer of $10,000 per month as a non-recoverable draw against any finder fees earned. The Company has also agreed to pay the consultant the sum of $5,500 per month for three years ($198,000 total) as a finder’s fee for introducing Genesys to the Company.
CY2019	rcrt	Settlement Value SettlementValue	10000	USD
CY2021	rcrt	Consulting Fees Expense ConsultingFeesExpense	13500	USD
CY2020	rcrt	Consulting Fees Expense ConsultingFeesExpense	54000	USD
CY2020	rcrt	Finders Fee Accured Compensation FindersFeeAccuredCompensation	104500	USD
CY2020	rcrt	Monthly Fee Expense Accrued MonthlyFeeExpenseAccrued	18000	USD
CY2021	us-gaap	Regulated Operating Revenue Other RegulatedOperatingRevenueOther	106842	USD
CY2020	us-gaap	Regulated Operating Revenue Other RegulatedOperatingRevenueOther	140642	USD
CY2021	rcrt	Employer Of Record Services Costs EmployerOfRecordServicesCosts	99904	USD
CY2020	rcrt	Employer Of Record Services Costs EmployerOfRecordServicesCosts	131546	USD
CY2021Q4	rcrt	Owes Icon Cost OwesIconCost	163672	USD
CY2020Q4	rcrt	Owes Icon Cost OwesIconCost	706515	USD
CY2021Q4	rcrt	Payment Of Icon PaymentOfIcon	49033	USD
CY2020Q4	rcrt	Payment Of Icon PaymentOfIcon	19143	USD
CY2021	us-gaap	Other Cost Of Operating Revenue OtherCostOfOperatingRevenue	498848	USD
CY2020	us-gaap	Other Cost Of Operating Revenue OtherCostOfOperatingRevenue	1232359	USD
CY2021	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	970	USD
CY2020	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	31041	USD
CY2021Q4	us-gaap	Accounts Receivable From Securitization AccountsReceivableFromSecuritization	22951	USD
CY2020Q4	us-gaap	Accounts Receivable From Securitization AccountsReceivableFromSecuritization	21981	USD
CY2020Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	28700000	USD
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	7100000	USD
CY2021	rcrt	Deferred Tax Carried Forward DeferredTaxCarriedForward	21600000	USD
CY2021	rcrt	Valuation Allowance Percentage ValuationAllowancePercentage	1	pure
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	3272000	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2029000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	6377	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3972	USD
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	350	USD
CY2020Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	728	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1717	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	19	USD
CY2020Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	4	USD
CY2021Q4	rcrt	Deferred Tax Asset Bad Debt Allowance DeferredTaxAssetBadDebtAllowance	221	USD
CY2020Q4	rcrt	Deferred Tax Asset Bad Debt Allowance DeferredTaxAssetBadDebtAllowance	11	USD
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	-942	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	16	USD
CY2021Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	241	USD
CY2020Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	20	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	7983	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	4711	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	7983	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4711	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	USD
CY2021	us-gaap	Income Tax Examination Description IncomeTaxExaminationDescription	In general, an ownership change, as defined by Section 382 and 383, results from transactions increasing ownership of certain stockholders or public groups in the stock of the corporation by more than 50 percentage points over a three-year period. The Company has not completed an IRC Section 382/383 analysis
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.21	pure
CY2021	rcrt	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate1 EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate1	-0.210	pure
CY2020	rcrt	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate1 EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate1	-0.210	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0210	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.001	pure
CY2021	rcrt	Effective Income Tax Rate Reconciliation Permanent Differences Overaccruals And Nondeductible Items EffectiveIncomeTaxRateReconciliationPermanentDifferencesOveraccrualsAndNondeductibleItems	0.0326	pure
CY2020	rcrt	Effective Income Tax Rate Reconciliation Permanent Differences Overaccruals And Nondeductible Items EffectiveIncomeTaxRateReconciliationPermanentDifferencesOveraccrualsAndNondeductibleItems	0.140	pure
CY2021	rcrt	Effective Income Tax Rate Reconciliation True Ups EffectiveIncomeTaxRateReconciliationTrueUps	-0.0019	pure
CY2020	rcrt	Effective Income Tax Rate Reconciliation True Ups EffectiveIncomeTaxRateReconciliationTrueUps	-0.051	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.2003	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.120	pure

Files In Submission

Name	View Source	Status
0001654954-22-004330-index-headers.html	Edgar Link	pending
0001654954-22-004330-index.html	Edgar Link	pending
0001654954-22-004330.txt	Edgar Link	pending
0001654954-22-004330-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
rcrt-20211231.xsd	Edgar Link	pending
rcrt-20211231_cal.xml	Edgar Link	unprocessable
rcrt-20211231_def.xml	Edgar Link	unprocessable
rcrt-20211231_lab.xml	Edgar Link	unprocessable
rcrt-20211231_pre.xml	Edgar Link	unprocessable
recruiter_10-kimg1.jpg	Edgar Link	pending
recruiter_10k.htm	Edgar Link	pending
recruiter_10k_htm.xml	Edgar Link	completed
recruiter_ex1019.htm	Edgar Link	pending
recruiter_ex1019img1.jpg	Edgar Link	pending
recruiter_ex1019img10.jpg	Edgar Link	pending
recruiter_ex1019img11.jpg	Edgar Link	pending
recruiter_ex1019img12.jpg	Edgar Link	pending
recruiter_ex1019img2.jpg	Edgar Link	pending
recruiter_ex1019img3.jpg	Edgar Link	pending
recruiter_ex1019img4.jpg	Edgar Link	pending
recruiter_ex1019img5.jpg	Edgar Link	pending
recruiter_ex1019img6.jpg	Edgar Link	pending
recruiter_ex1019img7.jpg	Edgar Link	pending
recruiter_ex1019img8.jpg	Edgar Link	pending
recruiter_ex1019img9.jpg	Edgar Link	pending
recruiter_ex1020.htm	Edgar Link	pending
recruiter_ex1020img25.jpg	Edgar Link	pending
recruiter_ex1020img26.jpg	Edgar Link	pending
recruiter_ex1020img27.jpg	Edgar Link	pending
recruiter_ex1020img28.jpg	Edgar Link	pending
recruiter_ex1020img29.jpg	Edgar Link	pending
recruiter_ex1020img30.jpg	Edgar Link	pending
recruiter_ex1020img31.jpg	Edgar Link	pending
recruiter_ex1020img32.jpg	Edgar Link	pending
recruiter_ex1020img33.jpg	Edgar Link	pending
recruiter_ex1020img34.jpg	Edgar Link	pending
recruiter_ex1020img35.jpg	Edgar Link	pending
recruiter_ex1020img36.jpg	Edgar Link	pending
recruiter_ex1021.htm	Edgar Link	pending
recruiter_ex1022.htm	Edgar Link	pending
recruiter_ex231.htm	Edgar Link	pending
recruiter_ex311.htm	Edgar Link	pending
recruiter_ex312.htm	Edgar Link	pending
recruiter_ex321.htm	Edgar Link	pending
recruiter_ex322.htm	Edgar Link	pending
recruiter_ex47.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NIXX
Nixxy, Inc. Stock $nixx

2021 Q4 Form 10-K Financial Statement

#000165495422004330 Filed on March 31, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NIXX Nixxy, Inc. Stock $nixx

2021 Q4 Form 10-K Financial Statement

#000165495422004330 Filed on March 31, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NIXX
Nixxy, Inc. Stock $nixx